Zoetis Inc (ZTS) Expected to Post Quarterly Sales of $1.39 Billion

Equities research analysts predict that Zoetis Inc (NYSE:ZTS) will post $1.39 billion in sales for the current quarter, according to Zacks. Four analysts have made estimates for Zoetis’ earnings, with estimates ranging from $1.37 billion to $1.41 billion. Zoetis posted sales of $1.27 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 9.4%. The business is expected to issue its next earnings results on Tuesday, August 14th.

According to Zacks, analysts expect that Zoetis will report full-year sales of $5.74 billion for the current financial year, with estimates ranging from $5.72 billion to $5.76 billion. For the next fiscal year, analysts expect that the business will post sales of $6.17 billion per share, with estimates ranging from $6.03 billion to $6.40 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Zoetis.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.06. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the firm posted $0.53 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis.



A number of brokerages have commented on ZTS. Hilliard Lyons lowered Zoetis to a “neutral” rating in a report on Thursday, April 19th. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and issued a $98.00 price objective (up from $85.00) on shares of Zoetis in a report on Thursday, April 19th. Cantor Fitzgerald set a $90.00 price objective on Zoetis and gave the company a “buy” rating in a report on Tuesday, April 24th. Morgan Stanley lowered Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price on the stock. in a report on Monday, March 19th. They noted that the move was a valuation call. Finally, Craig Hallum reissued a “buy” rating and set a $94.00 target price (up from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the stock. Zoetis has a consensus rating of “Buy” and an average price target of $84.25.

In related news, insider Kristin C. Peck sold 4,877 shares of the company’s stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the sale, the insider now directly owns 42,652 shares in the company, valued at approximately $3,559,735.92. The sale was disclosed in a filing with the SEC, which is available through this link. 0.35% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Gables Capital Management Inc. bought a new stake in shares of Zoetis during the 1st quarter worth $109,000. We Are One Seven LLC bought a new stake in shares of Zoetis during the 4th quarter worth $120,000. Premia Global Advisors LLC bought a new stake in shares of Zoetis during the 4th quarter worth $122,000. Icon Wealth Partners LLC bought a new stake in shares of Zoetis during the 4th quarter worth $127,000. Finally, Private Capital Group LLC lifted its position in shares of Zoetis by 118.4% during the 1st quarter. Private Capital Group LLC now owns 1,529 shares of the company’s stock worth $128,000 after buying an additional 829 shares during the last quarter. Institutional investors and hedge funds own 90.09% of the company’s stock.

Shares of NYSE ZTS opened at $87.25 on Wednesday. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. Zoetis has a one year low of $59.50 and a one year high of $89.25. The firm has a market capitalization of $43.16 billion, a price-to-earnings ratio of 36.35, a PEG ratio of 1.97 and a beta of 0.98.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.58%. The ex-dividend date is Thursday, July 19th. Zoetis’s dividend payout ratio (DPR) is currently 20.83%.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply